Drug Topics April 2019

The strategies these pharmacists followed to succeed.

What you need to know about the 340B litigations.

What you need to know about the serotonin-4 receptor agonist approved for adult patients.

Diffusing hostility requires empathy, communication, and patience.

Government and PBMs can pursue penalties for noncompliance. 

Key updates from the Seattle, WA, conference in March.

Like the idea of telpharmacy and not sure where to start? 

Increase adherence by matching technology to each patient's unique needs.

Rural markets pave way to treat underserved populations, provide value-based care, and expand prescription volume. 

 More than 25,000 lawsuits cite uncontrollable and irreversible bleeding and death. 

Patients taking PPIs 28.4 times more likely to develop chronic kidney disease. 

Aggregated data highlights manufacturers responsible for price increases. 

National Gold Status Practice created by a pharmacist looks to expand nationwide. 

Although requests for measles vaccinations are increasing, pharmacists may be limited by state laws.

ADA violations net pharmacist over $1 million. 

Only new biosimilars and interchangeables will recieve four-letter suffixes.

More than 40 companies have been recorded distributing nicotine-containing products to minors.

As sunscreens have evolved, new safety considerations are warranted.

Gerry Crocker talks with Drug Topics on his plans to grow the Association of Affiliated Pharmacies and Apothecaries (AAPArx).

Using Blockchain technology, the new program will legally redispense expensive medications to those who cannot afford them.

How you can manage these stereotypes found in the pharmacy workplace.